The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?

References

• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Chronic myelogenous leukemia (CML). Available from: http://marrow.org/Physicians/Unrelated_Search_and_Transplant/NMDP_Outcomes/CML_Outcomes/Chronic_Myelogenous_Leukemia_%28CML%29_Outcomes.aspx
   Google Scholar
• Bacher U, Klyuchnikov E, Zabelina T, et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009;88:1237–1247.
   PubMed Web of Science ®Google Scholar
• Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 2006;12:795–807.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041–2050.
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433–444.
   PubMed Web of Science ®Google Scholar
• Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707–1712.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590–1595.
   PubMed Web of Science ®Google Scholar
• Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia:results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583–7593.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10:5065–5071.
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1009–1015.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990;75:1370–1377.
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309: 1347–1353.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Khouri I, Thall P, et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999;23:977–981.
   PubMed Web of Science ®Google Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377–386.
   PubMed Web of Science ®Google Scholar
• Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224–3230.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
   PubMed Web of Science ®Google Scholar
• Aalen O, Johansen S. An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Stat 1978;5:141–150.
   Web of Science ®Google Scholar
• Klein JP, Szydlo RM, Craddock C, et al. Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. Stat Med 2000;19:3005–3016.
   PubMed Web of Science ®Google Scholar
• Carstensen B. Demography and epidemiology: Practical use of the Lexis diagram in the computer age, or: Who needs the Cox model anyway? Technical Report 06.2. Department of Biostatistics, University of Copenhagen, 2006. Available from: http://biostat.ku.dk/reports/2006/rr-06-2.pdf/
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–480.
   Web of Science ®Google Scholar
• R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
   Google Scholar
• Allignol A, Schumacher M, Beyersmann J. Empirical transition matrix of multistate models: the etm package. J Stat Softw 2011;38(4):1–15.
   Web of Science ®Google Scholar
• Carstensen B, Plummer M. Using Lexis objects for multistate models in R. J Stat Softw 2011;38(6):1–18.
   Web of Science ®Google Scholar
• de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 2010;99:261–274.
   PubMed Web of Science ®Google Scholar
• Shanavas M, Messner HA, Kamel-Reid S, et al. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 2014;14:87–92.
   PubMed Web of Science ®Google Scholar
• Logan BR. A review of multistate models in hematopoietic cell transplantation studies. Biol Blood Marrow Transplant 2013; 19(1 Suppl.):S84–S87.
   Google Scholar
• Al-Kali A, Kantarjian H, Shan J, et al. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 2011;117:327–335.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997;127:1080–1088.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–585.
   PubMed Web of Science ®Google Scholar
• Fang Y, Hein P. Probability prediction in multistate survival models for patients with chronic myeloid leukemia. J Huazhong Univ Sci Technolog Med Sci 2005;25:100–103.
   PubMedGoogle Scholar